Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors

被引：1

作者：

Zhang, J. ^{[1
]}

Liu, R. ^{[1
]}

Gao, S. ^{[1
]}

Li, X. ^{[2
]}

Chen, J. ^{[3
]}

Yao, X. ^{[4
]}

Fang, Y. ^{[5
]}

Li, R. ^{[6
]}

Zhang, M. ^{[7
]}

Qiu, F. ^{[8
]}

Li, Y. ^{[9
]}

Liu, T. ^{[10
]}

Huang, H. ^{[11
]}

Zhang, X. ^{[12
]}

Guo, H. ^{[13
]}

Hu, B. ^{[14
]}

Liu, J-Y. ^{[15
]}

Yang, Q. ^{[16
]}

Zhao, P. ^{[17
]}

Wang, P. ^{[18
]}

机构：

[1] Shanghai Canc Ctr, Phase I Clin Trial Ctr, Shanghai, Peoples R China

[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China

[3] Yantai Yuhunagding Hosp, Dept Med Oncol, Yantai, Peoples R China

[4] Tianjin Canc Hosp, Dept Urol Oncol, Tianjin, Peoples R China

[5] Affiliated Canc Hosp Chongqing Univ, Dept Urol, Chongqing, Peoples R China

[6] Chongqing Univ Canc Hosp, Gynecol Oncol Ctr, Chongqing, Peoples R China

[7] Second Hosp Anhui Med Univ, Dept Med Oncol, Hefei, Peoples R China

[8] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Med Oncol, East Gate 1, Hangzhou, Peoples R China

[9] Shenyang Tenth Peoples Hosp, Dept Oncol, Shenyang, Peoples R China

[10] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China

[11] Wenzhou Med Univ, Affiliated Hosp 1, Dept Urinary Surg, Nanbaixiang Site, Wenzhou, Peoples R China

[12] Wuhan Union Hosp, Dept Urol, Wuhan, Peoples R China

[13] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Urol, Nanjing, Peoples R China

[14] Liaoning Canc Hosp & Inst, Dept Urol, Shenyang, Peoples R China

[15] Sichuan Univ, West China Hosp, West China Sch Med, Dept Biotherapy, Chengdu, Peoples R China

[16] Sun Yat Sen Univ, Affiliated Hosp 2, Phase I Clin Trial Ctr, Guangzhou, Peoples R China

[17] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China

[18] Mabwell Shanghai Biosci Co Ltd, Clin Med Dept, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1845

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

659MO

引用

页码：S464 / S464

页数：1

共 50 条

[31] A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma
Hwu, P.
Sznol, M.
Pavlick, A.
Kluger, H.
Kim, K. B.
Boasberg, P.
Sanders, D.
Simantov, R.
Crowley, E.
Hamid, O.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[32] Phase I study of A166, an antibody-drug conjugate in advanced HER2-expressing solid tumours
Zhang, Jian
Liu, Rujiao
Gao, Shuiping
Li, Wenhua
Chen, Yang
Meng, Yanchun
Liu, Chang
Jin, Wenyue
Wu, Junyan
Wang, Ying
Hao, Yanrong
Yi, Shuli
Qing, Yan
Ge, Junyou
Hu, Xichun
NPJ BREAST CANCER, 2023, 9 (01)
[33] Praluzatamab Ravtansine, a CD166-Targeting Antibody- Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Boni, Valentina
Fidler, Mary J.
Arkenau, Hendrik-Tobias
Spira, Alexander
Meric-Bernstam, Funda
Uboha, Nataliya
Sanborn, Rachel E.
Sweis, Randy F.
LoRusso, Patricia
Nagasaka, Misako
Garcia-Corbacho, Javier
Jalal, Shadia
Harding, James J.
Kim, Stella K.
Miedema, Iris H. C.
Vugts, Danielle J.
Huisman, Marc C.
Zwezerijnen, Gerben J. C.
van Dongen, Guus A. M. S.
van Oordt, C. Willemien Menke van der Houven
Wang, Song
Dang, Tam
Zein, Ivan A.
Vasiljeva, Olga
Lyman, Susan K.
Paton, Virginia
Hannah, Alison
Liu, Joyce F.
CLINICAL CANCER RESEARCH, 2022, 28 (10) : 2020 - 2029
[34] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Lemech, Charlotte
Woodward, Natasha
Chan, Nancy
Mortimer, Joanne
Naumovski, Louie
Nuthalapati, Silpa
Tong, Bo
Jiang, Fang
Ansell, Peter
Ratajczak, Christine K.
Sachdev, Jasgit
INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1815 - 1825
[35] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Charlotte Lemech
Natasha Woodward
Nancy Chan
Joanne Mortimer
Louie Naumovski
Silpa Nuthalapati
Bo Tong
Fang Jiang
Peter Ansell
Christine K. Ratajczak
Jasgit Sachdev
Investigational New Drugs, 2020, 38 : 1815 - 1825
[36] Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Chandana, S.
Garmezy, B.
Dowlati, A.
Sharma, M. R.
Henner, W.
Robinson, R.
Hingorani, P.
Jeng, E.
Papadopoulos, K. P.
ANNALS OF ONCOLOGY, 2023, 34 : S1077 - S1077
[37] Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors
Sharma, Manish
Kuboki, Yasutoshi
Camidge, D. Ross
Perets, Ruth
Sommerhalder, David
Yamamoto, Noboru
Bar, Jair
Parikh, Apurvasena
Li, Rui
Thiele, Gladys Morrison
Aristide, Martha Raluca Neagu
Freise, Kevin Jay
Powderly, John D.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[38] Association of combined phase I/II study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with Nectin-4 expression.
McKean, Meredith
Falchook, Gerald Steven
Bendell, Johanna C.
Bashir, Babar
Palmisiano, Neil
Watson, Roshawn
McKenna, Mary-Anne
Campbell, Carly
Smethurst, Dominic Paul
Jeffrey, Phil
Kirui, Julius
Arkenau, Hendrik-Tobias
Fontana, Elisa
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial
Ma, Yuxiang
Yang, Yunpeng
Huang, Yan
Fang, Wenfeng
Xue, Jinhui
Meng, Xiangjiao
Fan, Yun
Fu, Siqing
Wu, Lin
Zheng, Yulong
Liu, Jian
Liu, Zhihua
Zhuang, Wu
Rosen, Seth
Qu, Song
Li, Bihui
Li, Mingjun
Zhao, Yanqiu
Yang, Shujun
Ji, Yinghua
Sommerhalder, David
Luo, Suxia
Yang, Kunyu
Li, Jingao
Lv, Dongqing
Zhang, Peng
Zhao, Yuanyuan
Hong, Shaodong
Zhang, Yang
Zhao, Shen
Chin, Steve
Zhang, Xian
Lian, Wei
Cai, Jiaqiang
Xue, Tongtong
Zhang, Li
Zhao, Hongyun
NATURE MEDICINE, 2025,
[40] Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors
Wang, Jiani
Tong, Zhongsheng
Tan, Yinuo
Shi, Yehui
Wu, Yun
Zhou, Qing
Xing, Xiaoyan
Chen, Xiaomei
Qiu, Fuming
Ma, Fei
CELL REPORTS MEDICINE, 2024, 5 (09)

← 1 2 3 4 5 →